Percentage of participants with functional cure (defined as percentage of participants with HBsAg seroclearance at 24 weeks after stopping all study interventions at the end of consolidation phase and without restarting NA treatment) were reported. Seroclearance HBsAg was defined as a (quantitative) HBsAg level \

Per protocol analysis set: all randomized/enrolled participants who received at least 1 dose of CP study intervention and did not had any of the selected major protocol deviations that might affect the assessment of efficacy in terms of the primary endpoint at 24 weeks after stopping all study interventions of the CP.

Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment.

Safety analysis set included all participants who received at least one dose of study intervention. Participants were analyzed according to the study intervention they actually received.

Number of participants with TESAEs were reported. was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Safety analysis set included all participants who received at least one dose of study intervention. Participants were analyzed according to the study intervention they actually received.

Clinical laboratory test parameters were Hematology: absolute lymphocyte count, absolute neutrophil count (ANC), hemoglobin, Neutrophils Band Form, Neutrophils segmented, white blood cells (WBC) decreased, ; Chemistry: alanine aminotransferase (ALT) & serum glutamic pyruvic transaminase (SGPT), aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT), cholesterol (fasting), creatinine Kinase, creatinine, GFR from Creatinine Adjusted for BSA, GFR from Cystatin C Adjusted for BSA, low-density lipoprotein (LDL), triglycerides (fasting); Urinalysis: glycosuria. DAIDS toxicity grades: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). Number of participants with treatment-emergent DAIDS toxicity Grade 3 or 4 were reported in this outcome measure.

Safety analysis set included all participants who received at least one dose of study intervention. Participants were analyzed according to the study intervention they actually received. Here, "n"(number analyzed) signifies number of participants analyzed at specified categories.

Number of participants with worst treatment-emergent abnormality in ECG were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. ECG parameters included heart rate (HR; abnormally low, HR <45 beats per minute (bpm) and (abnormally high HR>=120 bpm; PR interval abnormally high >220 milliseconds (ms): QRS interval abnormally high >=120 ms; QT corrected (Fridericia QTcF) categories; borderline prolonged QTc interval <450 to <=480 ms), prolonged QTc interval <480 to <=500 ms) and pathologically prolonged QTc interval >500 ms).

Safety analysis set included all participants who received at least one dose of study intervention. Participants were analyzed according to the study intervention they actually received.

Number of participants with worst treatment-emergent abnormalities in vital signs were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. Abnormalities in vital signs included abnormal pulse rate (PR); abnormally low, <=45 bpm and abnormally high >=120 bpm; diastolic blood pressure (DBP) abnormally low <=50 mmHg, systolic blood pressure (SBP) abnormally low <=90 mmHg. Additionally, abnormal low SBP and DBP were <=50 mmHg and <+90 mmHg. Only those categories in which at least one participant had data were reported.

Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analyzed according to the study intervention they actually received.

Number of participants with clinically important treatment-emergent abnormalities in physical examination were reported.

Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analyzed according to the study intervention they actually received.

Percentage of participants who reached HBsAg <10 IU/mL at the end induction phase were reported.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, "n"(number analyzed) signifies participants who were evaluable at specified timepoints. Data for this outcome measure were planned to be collected and analyzed for IP only.

Time to achieve first occurrence of HBsAg <10 IU/mL were reported. Time to HBsAg <10 IU/mL was defined as the number of days between the date of first study treatment intake and the date of the first occurrence of HBsAg <10 IU/mL. Kaplan-Meier method was used for the estimation.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.

Percentage of participants meeting the protocol-defined NA treatment completion criteria at end of consolidation were reported. NA treatment completion criteria at CP Week 12 was defined as HBsAg <10 IU/mL; HBeAg-negative; HBV DNA <20 IU/mL, (that is, LLOQ); alanine aminotransferase(ALT) <3*ULN.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure.

Percentage of participants with HBsAg seroclearance 48 weeks after stopping all study interventions at the consolidation phase and without restarting NA treatment during follow up phase were reported. HBsAg seroclearance was defined as (quantitative) HBsAg < LLOQ (HBsAg 0.05 IU/mL).

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.

Percentage of participants with HBV DNA \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants who were evaluable for this outcome measure. Here, N=0 signifies that data were not collected and analyzed for participants who stopped NA at the end of treatment.

Number of participants with off-treatment virologic HBV flares were reported. Virologic flare was defined as confirmed HBV DNA >peak threshold (lowest peak to qualify as virologic flare was HBV DNA >200 IU/mL) in participants who were off-treatment and had HBV DNA \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants who were evaluable for this outcome measure. Here, N=0 signifies that data were not collected and analyzed for participants who stopped NA at the end of treatment.

Number of participants with off-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST >=3*ULN and >=3*nadir (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. Off-treatment was defined as the time period after stopping all study treatments (including NA).

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants who were evaluable for this outcome measure. Here, N=0 signifies that data were not collected and analyzed for participants who stopped NA at the end of treatment.

Number of participants with on-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST >=3*ULN and >=3*nadir (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. On-treatment was defined as the time period during which the participant received any of the study drugs.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.

Clinical flares occurred either when a virologic flare (confirmed HBV DNA >peak threshold) & biochemical flare (ALT and/or AST >=3*ULN & >=3*nadir [lowest value observed during off-treatment period up to time point of meeting the flare criteria]) overlapped in time or when a biochemical flare started within 4 weeks following the end of a virologic flare. The HBV DNA thresholds were: 20,000 IU/mL, 2,000 IU/mL and 200 IU/mL. Confirmed means that criteria was fulfilled at 2 or more consecutive time points or at last observed time point. Off-treatment was defined as time period after stopping all study drugs (including NA). The start date of a clinical flare was minimum start date of virologic flare and biochemical flare.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants who were evaluable for this outcome measure. Here, N=0 signifies that data were not collected and analyzed for participants who stopped NA at the end of treatment.

Percentage of participants who required NA re-treatment during follow-up phase were reported. A responder was defined as a participant who met the criteria for NA re-treatment at any time during follow-up, for those participants who met the NA treatment completion criteria at any time during the study and actually stopped NA treatment.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants who were evaluable for this outcome measure. Here, N=0 signifies that data were not collected and analyzed for participants who stopped NA at the end of treatment.

Percentage of participants with sustained (reduction) HBsAg response (per Definition 1) were reported. Sustained HBsAg response (definition 1) was defined as: For participants with FU Week 48 data: participants who had a >1 log10 decline from baseline in HBsAg and HBsAg <000 IU/mL at FU Week 48. For participants without FU Week 48 data: participants who had a HBsAg decline from baseline of >2 log10 at FU Week 24 or >1.5 log10 at FU Week 36 (most recent value used) and had HBsAg <1000 IU/mL at the last available timepoint.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure.

Percentage of participants with sustained (reduction) HBsAg response (per Definition 2) were reported. Sustained HBsAg response (per Definition 2) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log10 HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log10 HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure.

Percentage of participants with sustained (reduction) HBsAg response (per definition 3) were reported. Sustained HBsAg response (per Definition 3) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log10 HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log10 HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2 and had an HBsAg <1000 IU/mL at the last available timepoint.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure.

Percentage of participants with sustained (reduction) HBsAg response per Definition 4 were reported. Sustained HBsAg response (per Definition 4) was defined as stable level, decreasing level, and increasing level. Stable level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was within 0.2 log10. Decreasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was less than -0.2 log10. Increasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was more than 0.2 log10.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.

Percentage of Participants with HBsAg Seroclearance were reported. HBsAg seroclearance was defined as (quantitative) HBsAg level \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure.

Percentage of participants with HBeAg seroclearance were reported. HBeAg seroclearance was defined as (quantitative) HBeAg levels \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.

Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance (defined as quantitative HBsAg <LLOQ [<0.05 IU/mL]) and appearance of anti-HBs antibodies (defined as a baseline anti-HBs antibodies [quantitative] <LLOQ [<5 milli-international units per milliliter (mIU/mL)] and a post-baseline assessment >=LLOQ [>=5 mIU/mL]).

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure and "n" (number analyzed) signifies participants evaluable at specified timepoints. Also, n=0 signifies that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Percentage of participants with HBeAg seroconversion were reported. Seroconversion of HBeAg was defined as having achieved HBeAg seroclearance (defined as [quantitative] HBeAg \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure and "n"(number analyzed) signifies participants evaluable at specified timepoints. Data were planned to be collected and analyzed for CP and FU phase only. Here, n=0, signify that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Change from baseline over time in HBsAg levels at specified timepoints were reported

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, n=0, signify that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Change from baseline over time in HBsAg levels at specified timepoints were reported.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, n=0, signify that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Change from baseline over time in HBV DNA Levels at Specified Timepoints were reported.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, n=0, signify that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Time to achieve first HBsAg seroclearance (defined as quantitative HBsAg \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this endpoint. Per planned analysis, data for this outcome measure was analyzed per pooled cohorts only.

Time to achieve first occurrence of HBeAg seroclearance (HBeAg \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure. Per planned analysis, data for this outcome measure was analyzed per pooled cohorts only.

Time to achieve first occurrence of HBV DNA < LLOQ (<20 IU/mL) were reported. Time to first occurrence of the HBV DNA < LLOQ was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBV DNA < LLOQ.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure. Per planned analysis, data for this outcome measure was analyzed per pooled cohorts only.

Percentage of participants with HBeAg levels below different cut-offs were reported. The cut-offs for HBeAg levels were : \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, n=0, signify that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Percentage of participants with HBsAg levels below different cut-offs were reported. The cut-offs for HBsAg level were: \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, n=0, signify that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Percentage of participants with HBV DNA levels below cut-offs were reported. The cut-offs for HBV DNA were as follows: \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure and "n"(number of participants analyzed) signifies participants analyzed at specified categories. Here, n=0, signify that data were not collected and analyzed as that timepoint was not applicable to the respective arm.

Percentage of participants with virologic breakthrough on treatment were reported. Virological breakthrough was defined as confirmed on-treatment HBV DNA increase by >1 log10 IU/mL from nadir level (lowest level reached during treatment) in participants who did not have on-treatment HBV DNA level < LLOQ (<20 IU/mL) or confirmed on-treatment HBV DNA level >200 IU/mL in participants who had on-treatment HBV DNA level \

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analyzed) signifies participants who were evaluable for this outcome measure.

Percentage of participants who reached HBV DNA undetectability after re-start of NA treatment during follow-up were reported. Undetectability of HBV DNA was defined as HBV DNA\

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here N=0 signifies that data could not be analyzed due to insufficient number of participants with events.

Cmax of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Noncompartmental analysis were conducted to analyze Cmax JNJ-73763989 and its molecules

Pharmacokinetics analysis set (PK): included participants who had received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Data for this outcome measure was planned to be collected and analyzed as pooled cohort in induction phase and consolidation phase only.

Time to reach the maximum observed plasma concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze tmax of JNJ-73763989 and its molecules.

Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Data for this endpoint was planned to be collected and analyzed as pooled cohort in induction phase and consolidation phase only.

Plasma concentration 24 hours after administration (C24h) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze C24h of JNJ-73763989 and its molecules.

Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this outcome measure. Data for this endpoint was planned to be collected and analyzed as pooled cohort in induction phase and consolidation phase only.

Area under the plasma concentration-time curve from time zero to 24hours (AUC0 to 24h) of JNJ-73763989 (molecules:JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted toanalyze AUC0 to 24h of JNJ-73763989 and its molecules.

Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this outcome measure. Data for this endpoint was planned to be collected and analyzed as pooled cohort in induction phase and consolidation phase only.